Rotavirus vaccines: current status and future considerations
#MMPMID24755452
Yen C
; Tate JE
; Hyde TB
; Cortese MM
; Lopman BA
; Jiang B
; Glass RI
; Parashar UD
Hum Vaccin Immunother
2014[]; 10
(6
): 1436-48
PMID24755452
show ga
Rotavirus is the leading cause of severe diarrhea among children<5 years
worldwide. Currently licensed rotavirus vaccines have been efficacious and
effective, with many countries reporting substantial declines in diarrheal and
rotavirus-specific morbidity and mortality. However, the full public health
impact of these vaccines has not been realized. Most countries, including those
with the highest disease burden, have not yet introduced rotavirus vaccines into
their national immunization programs. Research activities that may help inform
vaccine introduction decisions include (1) establishing effectiveness, impact,
and safety for rotavirus vaccines in low-income settings; (2) identifying
potential strategies to improve performance of oral rotavirus vaccines in
developing countries, such as zinc supplementation; and (3) pursuing alternate
approaches to oral vaccines, such as parenteral immunization. Policy- and
program-level barriers, such as financial implications of new vaccine
introductions, should be addressed to ensure that countries are able to make
informed decisions regarding rotavirus vaccine introduction.
|Diarrhea/epidemiology/prevention & control
[MESH]
|Drug Discovery/*trends
[MESH]
|Humans
[MESH]
|Rotavirus Infections/epidemiology/*prevention & control
[MESH]
free
free
free
